<DOC>
	<DOCNO>NCT00037700</DOCNO>
	<brief_summary>The purpose study evaluate effect anakinra ( IL-1 ra ) pegsunercept ( PEG sTNF-RI ) use together improve sign symptom rheumatoid arthritis . The study also evaluate safety combination treatment effect slow bone joint destruction due rheumatoid arthritis . The result compare effect 1 single medication ( anakinra pegsunercept ) use .</brief_summary>
	<brief_title>Evaluation Efficacy Combination Treatment With Anakinra Pegsunercept Improving Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>diagnose rheumatoid arthritis least 6 month must take methotrexate * must take DMARDS methotrexate study must previous treatment proteinbased TNFalpha inhibitor ( eg . etanercept , infliximab , PEG sTNFRI , D2E7 ) must previous treatment anakinra subject must meet tender swell joint requirement screen , morning stiffness , and/or elevate acute phase reactant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>